PARIS (Reuters) – The National Financial Prosecutor’s Office (PNF) opened a preliminary investigation in March into charges of dissemination of false or misleading information and price manipulation, entrusted to the financial brigade, relating to the financial communication of the Sanofi group, we learned on Tuesday from a judicial source.
According to the investigative media La Lettre, which revealed the information, the investigation concerns the launch in 2017 of one of the French laboratory’s star drugs, Dupixent.
Contacted by Reuters, Sanofi said it was “not aware of any preliminary investigation by the National Financial Prosecutor’s Office into its 2017 accounts or otherwise.”
“As a listed company, the financial information that Sanofi publishes is accurate, precise and truthful, and is also duly audited by two auditing firms. Sanofi reserves the right to take legal action against any false or defamatory allegations “, added the group.
On the Paris Stock Exchange, Sanofi shares fell 1.38% at 10:45 GMT, while the CAC 40 fell 0.36%.
(Tassilo Hummel, written by Jean-Stéphane Brosse, edited by Kate Entringer and Blandine Hénault)
Copyright © 2023 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
